Robeco Institutional Asset Management B.V. increased its position in ABIOMED, Inc. (NASDAQ:ABMD) by 57.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 44,111 shares of the medical equipment provider’s stock after buying an additional 16,025 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.10% of ABIOMED worth $19,838,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of ABIOMED by 1.6% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 9,139 shares of the medical equipment provider’s stock worth $3,738,000 after purchasing an additional 146 shares in the last quarter. World Asset Management Inc lifted its holdings in shares of ABIOMED by 5.2% in the 3rd quarter. World Asset Management Inc now owns 2,976 shares of the medical equipment provider’s stock worth $1,338,000 after purchasing an additional 146 shares in the last quarter. Wealthsource Partners LLC lifted its holdings in shares of ABIOMED by 24.6% in the 2nd quarter. Wealthsource Partners LLC now owns 887 shares of the medical equipment provider’s stock worth $363,000 after purchasing an additional 175 shares in the last quarter. Advisor Partners LLC lifted its holdings in shares of ABIOMED by 26.4% in the 2nd quarter. Advisor Partners LLC now owns 1,057 shares of the medical equipment provider’s stock worth $432,000 after purchasing an additional 221 shares in the last quarter. Finally, Balasa Dinverno & Foltz LLC lifted its holdings in shares of ABIOMED by 9.7% in the 2nd quarter. Balasa Dinverno & Foltz LLC now owns 2,647 shares of the medical equipment provider’s stock worth $1,083,000 after purchasing an additional 235 shares in the last quarter. 87.27% of the stock is owned by institutional investors.

A number of brokerages recently issued reports on ABMD. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a report on Wednesday, September 5th. Morgan Stanley raised ABIOMED from an “equal” rating to a “weight” rating and increased their price target for the company from $396.00 to $496.00 in a research report on Wednesday, November 7th. BTIG Research raised ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 price target for the company in a research report on Friday, November 2nd. Finally, ValuEngine lowered ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 18th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $402.78.

Shares of ABMD stock traded down $15.46 on Friday, hitting $317.52. 447,488 shares of the stock were exchanged, compared to its average volume of 688,005. The company has a market capitalization of $15.00 billion, a price-to-earnings ratio of 129.60, a PEG ratio of 2.72 and a beta of 0.28. ABIOMED, Inc. has a one year low of $187.01 and a one year high of $459.75.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, November 1st. The medical equipment provider reported $1.09 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.36. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. The company had revenue of $181.78 million during the quarter, compared to the consensus estimate of $175.41 million. During the same quarter in the prior year, the company earned $0.54 EPS. The firm’s quarterly revenue was up 36.9% compared to the same quarter last year. On average, analysts predict that ABIOMED, Inc. will post 3.57 EPS for the current fiscal year.

In other ABIOMED news, VP Michael G. Howley sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $432.50, for a total value of $4,325,000.00. Following the completion of the transaction, the vice president now owns 48,954 shares in the company, valued at approximately $21,172,605. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.50% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Marea Informative and is the property of of Marea Informative. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.mareainformativa.com/news/2018/12/08/robeco-institutional-asset-management-b-v-buys-16025-shares-of-abiomed-inc-abmd-updated-updated-updated.html.

ABIOMED Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Further Reading: What are no-load funds?

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.